DS
JNCE

David Shaw’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

David Shaw’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-52,462
Closed -$159K – 5694
2022
Q2 		$159K Buy
+52,462
New +$255K ﹤0.01% 4616
2022
Q1 		– Sell
-68,776
Closed -$574K – 6145
2021
Q4 		$574K Buy
68,776
+34,388
+100% +$283K ﹤0.01% 4328
2021
Q3 		$256K Sell
34,388
-44,535
-56% -$276K ﹤0.01% 4448
2021
Q2 		$537K Buy
+78,923
New +$656K ﹤0.01% 4005
2020
Q3 		– Sell
-24,367
Closed -$168K – 4274
2020
Q2 		$168K Buy
+24,367
New +$131K ﹤0.01% 3814
2020
Q1 		– Sell
-34,068
Closed -$298K – 4369
2019
Q4 		$298K Sell
34,068
-132,970
-80% -$719K ﹤0.01% 3630
2019
Q3 		$557K Buy
167,038
+33,595
+25% +$134K ﹤0.01% 3163
2019
Q2 		$660K Sell
133,443
-40,365
-23% -$214K ﹤0.01% 2926
2019
Q1 		$1.08M Buy
173,808
+80,032
+85% +$387K ﹤0.01% 2568
2018
Q4 		$316K Buy
93,776
+24,572
+36% +$115K ﹤0.01% 3318
2018
Q3 		$450K Buy
+69,204
New +$515K ﹤0.01% 3168
2018
Q2 		– Sell
-30,879
Closed -$690K – 3947
2018
Q1 		$690K Buy
+30,879
New +$685K ﹤0.01% 2731
2017
Q3 		– Sell
-19,323
Closed -$271K – 3663
2017
Q2 		$271K Sell
19,323
-917
-5% -$19.6K ﹤0.01% 3068
2017
Q1 		$445K Buy
+20,240
New +$429K ﹤0.01% 2784

Other funds holding JNCE

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

David Shaw's JNCE Position: Q3 2022 in Review

David Shaw sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2022, closing a stake of 52,462 shares — an estimated $159K sold.

David Shaw first reported a position in JNCE in Q1 2017 and held it in 14 quarters. The position peaked at $1.08M in Q1 2019. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

  • David Shaw reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • David Shaw sold 52,462 Jounce Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $159K.
  • David Shaw first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 14 quarters.
  • David Shaw's Jounce Therapeutics, Inc. Common Stock position peaked at $1.08M in Q1 2019.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.